NONOF News and Press, Novo-Nordisk A/S From 06/04/24

2024-06-04 13:50:00 ET Summary More than 800 million people are estimated to be overweight or obese worldwide, and the growing prevalence of obesity, despite the availability of various treatments, suggests that isn’t going to change. The potential $500 billion market for G...

2024-06-03 20:03:51 ET Summary Soros Fund Management's 13F portfolio value decreased from $7.65B to $6.02B in Q1 2024. New stakes include Cloudflare Inc. Puts, Cerevel Therapeutics, and Aramark. Stake disposals include Apple Puts, PDD Holdings Puts, and SPDR Index Euro Stocks ...

2024-05-30 11:22:06 ET More on Eli Lilly, Novo, etc. Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo Nordisk: Considerable Growth Beyond Ozempic Lilly's Retevmo gains appro...

2024-05-29 10:30:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...

2024-05-29 09:25:00 ET Summary Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affi...

2024-05-28 21:19:27 ET Summary Chase Coleman's Tiger Global Management 13F portfolio value increased from $14.1B to $18.3B this quarter. The largest five positions in the portfolio are Meta Platforms, Microsoft, Alphabet, Apollo Global, and Amazon.com. New stakes include Liber...

2024-05-28 14:36:30 ET Summary Calamos Global Dynamic Income Fund offers high-income and geographic diversification, without sacrificing equity exposure. The fund's distribution yield of 9.00% is lower than its peers, but it has delivered strong recent performance and total return...

2024-05-28 06:19:07 ET Summary Novo Nordisk reported great first quarter results again but free cash flow declined - in part due to high capital expenditures. At this point, we can expect the obesity market to continue growing with a high pace, but we should not ignore the increas...

2024-05-26 22:40:47 ET Summary Novo Nordisk is a Danish pharmaceutical company specializing in treatments for diabetes, obesity, and rare diseases. The company's main source of income comes from diabetes treatments, including insulin products and GLP-1 receptor agonists. Novo ...

2024-05-25 08:41:46 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Novo Nordisk once weekly insulin fails to get thu...